|
Naltrexone is effective for Alaska Natives and other Alaskans living in rural areas
May 12, 2008Access to treatment for alcohol dependence (AD) in rural and remote areas is limited. This study evaluated the effectiveness of two pharmacotherapies for AD - naltrexone alone, and in combination with sertraline - among Alaska Natives (ANs) and other Alaskans living in rural settings. Findings indicate that naltrexone is just as effective on its own as it is in combination with sertraline.
Results will be published in the July issue of Alcoholism: Clinical & Experimental Research and are currently available at OnlineEarly.
"In 1994, naltrexone was the first medication to be approved by the Food and Drug Administration for the treatment of AD," said Stephanie S. O'Malley, professor of psychiatry at Yale University School of Medicine and first author of the study. "Since then, numerous studies have shown its effectiveness. However, almost all of these studies were completed in urban settings in academically oriented clinics, and few if any Alaska Natives or American Indians were enrolled in these studies. In addition, it became clear that not all individuals benefit from naltrexone. For this reason, researchers have been investigating if different medications can be combined with naltrexone to increase its effectiveness."
Given that previous rodent research had suggested that sertraline could potentially reduce the likelihood of drinking in response to stress, and that naltrexone was known to reduce the amount consumed if someone lapsed, the study authors thought a combination of the two might increase abstinence rates more than using naltrexone alone.
Participants in this randomized, controlled study comprised 101 Alaskans with AD: 68 American Indians (AIs) and/or ANs, and 33 non-AIs/ANs. All received one of three 16-week treatments: naltrexone + sertraline placebo, naltrexone monotherapy (50 mg) + sertraline placebo, or naltrexone + sertraline (100 mg). All three treatments included nine sessions of medical management and supportive advice.
"Contrary to our hypothesis, the combination of naltrexone and sertraline was no better than naltrexone alone," said O'Malley. "We did, however, find that naltrexone significantly improved abstinence rates compared to placebo. For example, 35 percent of those on naltrexone remained abstinent for the entire 16-week treatment whereas only 12 percent of those in the placebo group did. The number of people who experienced consequences due to drinking was also significantly less in the naltrexone group. In summary, naltrexone was shown to be an efficacious treatment for AD among geographically isolated and rural Alaskans, including those of AI/AN descent."
O'Malley said these findings are important for all individuals with AD living in rural or remote areas.
"More than one-fifth of the U.S. population lives in rural or remote areas, and many of these areas have high rates of AD," she said. "Our study suggests that naltrexone in combination with a primary-care model of counseling could be used to treat alcoholism in these settings. This approach could increase access to care and reduce the consequences of alcoholism in these communities."
Alcoholism: Clinical & Experimental Research
Given that previous rodent research had suggested that sertraline could potentially reduce the likelihood of drinking in response to stress, and that naltrexone was known to reduce the amount consumed if someone lapsed, the study authors thought a combination of the two might increase abstinence rates more than using naltrexone alone.
Participants in this randomized, controlled study comprised 101 Alaskans with AD: 68 American Indians (AIs) and/or ANs, and 33 non-AIs/ANs. All received one of three 16-week treatments: naltrexone + sertraline placebo, naltrexone monotherapy (50 mg) + sertraline placebo, or naltrexone + sertraline (100 mg). All three treatments included nine sessions of medical management and supportive advice.
"Contrary to our hypothesis, the combination of naltrexone and sertraline was no better than naltrexone alone," said O'Malley. "We did, however, find that naltrexone significantly improved abstinence rates compared to placebo. For example, 35 percent of those on naltrexone remained abstinent for the entire 16-week treatment whereas only 12 percent of those in the placebo group did. The number of people who experienced consequences due to drinking was also significantly less in the naltrexone group. In summary, naltrexone was shown to be an efficacious treatment for AD among geographically isolated and rural Alaskans, including those of AI/AN descent."
O'Malley said these findings are important for all individuals with AD living in rural or remote areas.
"More than one-fifth of the U.S. population lives in rural or remote areas, and many of these areas have high rates of AD," she said. "Our study suggests that naltrexone in combination with a primary-care model of counseling could be used to treat alcoholism in these settings. This approach could increase access to care and reduce the consequences of alcoholism in these communities."
Alcoholism: Clinical & Experimental Research
Naltrexone News and Current Naltrexone Events RSSDrug commonly used for alcoholism curbs urges of pathological gamblers
A drug commonly used to treat alcohol addiction has a similar effect on pathological gamblers - it curbs the urge to gamble and participate in gambling-related behavior, according to a new research at the University of Minnesota.
Gene variant predicts medication response in patients with alcohol dependence
Patients with a certain gene variant drank less and experienced better overall clinical outcomes than patients without the variant while taking the medication naltrexone, according to an analysis of participants in the National Institutes of Health's 2001-2004 COMBINE (Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence) Study.
Microneedles enhance drug administration through skin
In what is believed to be the first peer-reviewed study of its kind involving human subjects, researchers at the University of Kentucky College of Pharmacy and the Georgia Institute of Technology have demonstrated that patches coated on one side with microscopic needles can facilitate transdermal delivery of clinically-relevant doses of a drug that normally cannot pass through the skin.
Elsevier
Naltrexone is one of four oral medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of alcoholism.
Data demonstrates alcohol does not significantly affect pharmacokinetics of Kadian
Alpharma Inc. (NYSE: ALO), a leading global specialty pharmaceutical company, presented results of a Phase IV study of KADIAN® (morphine sulfate extended-release) Capsules that demonstrate the pharmacokinetics of the long-acting opioid are not significantly affected by the consumption of alcohol.
Pilot study shows withdrawal drug offers symptom relief to Crohn's sufferers
A Penn State College of Medicine pilot study suggests a low dose of naltrexone, a drug used to ease symptoms of alcohol and drug addiction, may also bring relief to people with Crohn's disease, a chronic inflammatory disorder of the intestine that affects an estimated 500,000 Americans.
The G allele of the mu-opioid receptor gene is linked to craving for alcohol
The study of genes and their influence on alcohol consumption can operate on many different levels. Some studies examine how genes may interact with the environment, some look specifically at family history of alcohol dependence, and some zero in on "pieces" of genes and their influence on drinking.
Drug may help women stop smoking
Adding the opiate blocker naltrexone to the combination of behavioral therapy and nicotine patches boosted smoking cessation rates for women by almost 50 percent when assessed after eight weeks of treatment.
DNA highly-promising predictor for successful treatment of alcoholics
According to Dutch researcher Wendy Ooteman, the biological and genetic characteristics of alcoholics can predict which drugs will best suppress the desire to drink.
Alcoholism-treatment medication acamprosate may help abstinent alcoholics sleep better
Alcoholics generally don't sleep well. Nor does abstinence improve the situation much. In fact, sleep difficulties during alcohol abstinence may be responsible for a relapse to alcoholism as individuals attempt to self medicate their sleeping problems.
More Naltrexone News Articles
| © 2008 BrightSurf.com |